sarepta therapeutics - Search News

News

Sarepta Therapeutics, gene

Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug

Key Takeaways Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died.The patient was being treated for Duchenne muscular dystrophy,

· 1d · on MSN

Sarepta shares crash as second patient dies after receiving its gene therapy

· 1d · on MSN

Second patient death reported with gene therapy for muscular dystrophy

1don MSN

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More

Stocks were rising Monday after The Wall Street Journal reported Tehran was looking to resume talks with the White House over ...

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...

Health Care Down as Biotech Slides -- Health Care Roundup

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...

STAT7h

Lilly adds highest Zepbound doses to DTC offering

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

Explore more

Elevidys

Duchenne muscular dystrophy

Results that may be inaccessible to you are currently showing.

Hide inaccessible results